We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$2.07B
$13.9M 0.06%
428,120
– –
IMMU
52
DELISTED
Immunomedics Inc
IMMU
$11.7M 0.05%
330,000
+20,000
+6% +$585K
ANAB icon
53
AnaptysBio
ANAB
$1.71B
$11.5M 0.05%
513,677
+279,085
+119% +$5.1M
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$5.87B
$11.4M 0.05%
583,333
– –
AIMT
55
DELISTED
Aimmune Therapeutics
AIMT
$11.3M 0.05%
673,908
– –
HZNP
56
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.1M 0.05%
200,000
– –
QURE icon
57
uniQure
QURE
$3.36B
$10.4M 0.05%
230,883
-126,200
-35% -$7.45M
XENE icon
58
Xenon Pharmaceuticals
XENE
$5.88B
$10M 0.04%
+799,102
New +$10.2M
UROV
59
DELISTED
Urovant Sciences Ltd.
UROV
$9.84M 0.04%
1,000,000
– –
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
$9.78M 0.04%
369,047
– –
KRTX
61
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.14M 0.04%
81,976
+40,000
+95% +$3.48M
FLGT icon
62
Fulgent Genetics
FLGT
$548M
$9.11M 0.04%
569,444
– –
SGMO
63
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.96M 0.04%
999,823
– –
RETA
64
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.73M 0.04%
55,983
– –
ISEE
65
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.34M 0.04%
1,635,501
– –
ACGN
66
DELISTED
Aceragen Inc
ACGN
$8.25M 0.04%
271,376
– –
HOOK
67
DELISTED
HOOKIPA Pharma
HOOK
$8.14M 0.04%
70,048
– –
AUTL
68
Autolus Therapeutics
AUTL
$641M
$7.79M 0.03%
485,624
+328,851
+210% +$3.65M
PASG icon
69
Passage Bio
PASG
$14.3M
$7.52M 0.03%
13,750
– –
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.36M 0.03%
69,017
– –
CABA icon
71
Cabaletta Bio
CABA
$531M
$7.09M 0.03%
636,363
– –
ALEC icon
72
Alector
ALEC
$264M
$6.84M 0.03%
280,000
– –
BNR
73
Burning Rock Biotech
BNR
$103M
$6.75M 0.03%
+25,000
New +$6.85M
TARA icon
74
Protara Therapeutics
TARA
$228M
$5.85M 0.03%
199,671
– –
LEGN icon
75
Legend Biotech
LEGN
$4.24B
$5.75M 0.03%
+135,000
New +$5.27M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2020 Portfolio in Review

As of Q2 2020, Julian Baker held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Julian Baker added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Julian Baker's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Julian Baker fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Julian Baker's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Julian Baker opened 14 new positions and closed 10 in Q2 2020.
  • Julian Baker's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.